{"hands_on_practices": [{"introduction": "This exercise begins at the molecular design stage of translational medicine, exploring how a fundamental biophysical parameter of a Chimeric Antigen Receptor (CAR)—its binding affinity, or $K_d$—translates into a clinically relevant outcome. By modeling cytokine production as a function of CAR-antigen engagement, you will quantify how engineering a higher-affinity CAR can dramatically amplify the resulting cytokine burden. This practice highlights the critical link between molecular engineering and the potential for iatrogenic toxicity, a core concept in the development of cellular therapies [@problem_id:5027815].", "problem": "A clinical translation team is modeling cytokine production kinetics to proactively manage Cytokine Release Syndrome (CRS) and immune effector cell-associated neurotoxicity after infusion of Chimeric Antigen Receptor (CAR) T cells. Consider a CAR construct with Cluster of Differentiation 28 (CD28) co-stimulation targeting a membrane antigen presented at an effective synaptic concentration of $A$ (in nM). Let $K_d$ (in nM) be the equilibrium dissociation constant of the CAR–antigen interaction. Assume the following foundational base:\n\n- At quasi-steady-state in the immunological synapse, the fraction of engaged CARs is given by the mass-action occupancy $ \\theta = \\dfrac{A}{A + K_d} $.\n- Intracellular signal transduction with CD28 co-stimulation exhibits ultrasensitivity that can be coarse-grained by a Hill transduction with coefficient $n$, so that the cytokine production rate per unit volume for cytokine $i$ is $ r_i = p_{i,\\max} \\, \\theta^{n} $, where $p_{i,\\max}$ (in pg mL$^{-1}$ h$^{-1}$) is the maximal production rate at full engagement.\n- Cytokine clearance is first-order: for cytokine $i$ with concentration $C_i(t)$ (in pg mL$^{-1}$), $ \\dfrac{dC_i}{dt} = r_i - k_i C_i $, with initial condition $ C_i(0) = 0 $, and $k_i$ (in h$^{-1}$) the elimination rate constant.\n\nYou are given two cytokines critical for CRS risk: Interferon gamma (IFN-$\\gamma$) and Interleukin-2 (IL-2). For a CD28-costimulated CAR product, take the Hill coefficient to be $n = 2$. For IFN-$\\gamma$, let $p_{\\mathrm{IFN},\\max} = 240$ pg mL$^{-1}$ h$^{-1}$ and a plasma half-life of $t_{1/2,\\mathrm{IFN}} = 0.50$ h. For IL-2, let $p_{\\mathrm{IL2},\\max} = 150$ pg mL$^{-1}$ h$^{-1}$ and a plasma half-life of $t_{1/2,\\mathrm{IL2}} = 0.25$ h. Assume the effective antigen concentration is $A = 5$ nM.\n\nDefine the $24$-hour total cytokine burden as the area under the combined concentration–time curve:\n$$\nB(T) \\equiv \\int_{0}^{T} \\big( C_{\\mathrm{IFN}}(t) + C_{\\mathrm{IL2}}(t) \\big) \\, dt,\n$$\nwith $T = 24$ h.\n\nSuppose the initial CAR has affinity $K_d^{(\\mathrm{old})} = 10$ nM and is then re-engineered to a higher affinity $K_d^{(\\mathrm{new})} = 1$ nM, with all other parameters unchanged. Using only the principles and assumptions stated above, compute the fold-change in the $24$-hour total cytokine burden\n$$\nR \\equiv \\dfrac{B^{(\\mathrm{new})}(24 \\ \\mathrm{h})}{B^{(\\mathrm{old})}(24 \\ \\mathrm{h})}.\n$$\nExpress your final answer as a unitless ratio and round your answer to three significant figures.", "solution": "The problem requires the computation of the fold-change in total cytokine burden when a Chimeric Antigen Receptor (CAR) T cell is re-engineered for higher affinity. The solution involves modeling the kinetics of cytokine production and clearance.\n\nFirst, we must validate the problem statement.\nThe problem is scientifically grounded, employing standard pharmacokinetic and pharmacodynamic models: mass-action for receptor binding, the Hill equation for sigmoidal response, and first-order kinetics for elimination. All parameters and constants are provided, and the objective is clearly defined. The problem is self-contained, objective, and well-posed. There are no scientific or logical contradictions, making it a valid problem to solve.\n\nLet us proceed with the derivation.\n\nThe concentration of a given cytokine $i$, denoted by $C_i(t)$, is governed by the first-order linear ordinary differential equation:\n$$\n\\frac{dC_i}{dt} = r_i - k_i C_i\n$$\nwith the initial condition $C_i(0) = 0$. Here, $r_i$ is the production rate and $k_i$ is the elimination rate constant.\n\nThe production rate $r_i$ is given by:\n$$\nr_i = p_{i,\\max} \\, \\theta^{n}\n$$\nwhere $p_{i,\\max}$ is the maximal production rate, $n$ is the Hill coefficient, and $\\theta$ is the fraction of engaged CARs. The problem states that $n=2$. The occupancy $\\theta$ is determined by the law of mass action:\n$$\n\\theta = \\frac{A}{A + K_d}\n$$\nwhere $A$ is the effective antigen concentration and $K_d$ is the equilibrium dissociation constant. Since $A$ and $K_d$ are constant for a given scenario, $\\theta$ is also a constant, which means the production rate $r_i$ is constant with respect to time $t$.\n\nThe differential equation is a standard first-order linear ODE with a constant forcing term. The solution with the initial condition $C_i(0) = 0$ is:\n$$\nC_i(t) = \\frac{r_i}{k_i} (1 - \\exp(-k_i t))\n$$\nThe elimination rate constant $k_i$ is related to the half-life $t_{1/2,i}$ by $k_i = \\frac{\\ln(2)}{t_{1/2,i}}$. However, we will see that the numerical values of $k_i$ are not required for the final ratio.\n\nThe total cytokine burden over a period $T$ is defined as:\n$$\nB(T) = \\int_{0}^{T} \\left( C_{\\mathrm{IFN}}(t) + C_{\\mathrm{IL2}}(t) \\right) dt = \\int_{0}^{T} C_{\\mathrm{IFN}}(t) dt + \\int_{0}^{T} C_{\\mathrm{IL2}}(t) dt\n$$\nLet us compute the integral for a generic cytokine $i$.\n$$\nB_i(T) = \\int_{0}^{T} C_i(t) dt = \\int_{0}^{T} \\frac{r_i}{k_i} (1 - \\exp(-k_i t)) dt\n$$\n$$\nB_i(T) = \\frac{r_i}{k_i} \\left[ t + \\frac{1}{k_i}\\exp(-k_i t) \\right]_{0}^{T} = \\frac{r_i}{k_i} \\left( \\left(T + \\frac{1}{k_i}\\exp(-k_i T)\\right) - \\left(0 + \\frac{1}{k_i}\\exp(0)\\right) \\right)\n$$\n$$\nB_i(T) = \\frac{r_i}{k_i^2} \\left( k_i T - 1 + \\exp(-k_i T) \\right)\n$$\nThe total burden $B(T)$ is the sum of the individual burdens for IFN-$\\gamma$ and IL-2:\n$$\nB(T) = B_{\\mathrm{IFN}}(T) + B_{\\mathrm{IL2}}(T)\n$$\n$$\nB(T) = \\frac{r_{\\mathrm{IFN}}}{k_{\\mathrm{IFN}}^2} \\left( k_{\\mathrm{IFN}} T - 1 + \\exp(-k_{\\mathrm{IFN}} T) \\right) + \\frac{r_{\\mathrm{IL2}}}{k_{\\mathrm{IL2}}^2} \\left( k_{\\mathrm{IL2}} T - 1 + \\exp(-k_{\\mathrm{IL2}} T) \\right)\n$$\nNow, we substitute the expression for the production rates, $r_{\\mathrm{IFN}} = p_{\\mathrm{IFN},\\max} \\theta^n$ and $r_{\\mathrm{IL2}} = p_{\\mathrm{IL2},\\max} \\theta^n$.\n$$\nB(T) = \\frac{p_{\\mathrm{IFN},\\max} \\theta^n}{k_{\\mathrm{IFN}}^2} \\left( k_{\\mathrm{IFN}} T - 1 + \\exp(-k_{\\mathrm{IFN}} T) \\right) + \\frac{p_{\\mathrm{IL2},\\max} \\theta^n}{k_{\\mathrm{IL2}}^2} \\left( k_{\\mathrm{IL2}} T - 1 + \\exp(-k_{\\mathrm{IL2}} T) \\right)\n$$\nWe can factor out the term $\\theta^n$:\n$$\nB(T) = \\theta^n \\left[ \\frac{p_{\\mathrm{IFN},\\max}}{k_{\\mathrm{IFN}}^2} \\left( k_{\\mathrm{IFN}} T - 1 + \\exp(-k_{\\mathrm{IFN}} T) \\right) + \\frac{p_{\\mathrm{IL2},\\max}}{k_{\\mathrm{IL2}}^2} \\left( k_{\\mathrm{IL2}} T - 1 + \\exp(-k_{\\mathrm{IL2}} T) \\right) \\right]\n$$\nThe problem compares two scenarios: an initial (\"old\") CAR and a re-engineered (\"new\") CAR. The only parameter that changes between these scenarios is the dissociation constant $K_d$. All other parameters ($p_{i,\\max}$, $k_i$, $n$, $A$, $T$) are stated to be unchanged.\nThe term in the square brackets depends only on these unchanged parameters. Let us denote this constant term as $S$:\n$$\nS = \\left[ \\frac{p_{\\mathrm{IFN},\\max}}{k_{\\mathrm{IFN}}^2} \\left( k_{\\mathrm{IFN}} T - 1 + \\exp(-k_{\\mathrm{IFN}} T) \\right) + \\frac{p_{\\mathrm{IL2},\\max}}{k_{\\mathrm{IL2}}^2} \\left( k_{\\mathrm{IL2}} T - 1 + \\exp(-k_{\\mathrm{IL2}} T) \\right) \\right]\n$$\nThus, the total burden $B(T)$ is directly proportional to $\\theta^n$:\n$$\nB(T) = S \\cdot \\theta^n\n$$\nThe desired fold-change $R$ is the ratio of the new burden to the old burden:\n$$\nR = \\frac{B^{(\\mathrm{new})}(T)}{B^{(\\mathrm{old})}(T)} = \\frac{S \\cdot (\\theta^{(\\mathrm{new})})^n}{S \\cdot (\\theta^{(\\mathrm{old})})^n} = \\left(\\frac{\\theta^{(\\mathrm{new})}}{\\theta^{(\\mathrm{old})}}\\right)^n\n$$\nThis elegant simplification significantly reduces the calculation, bypassing the need to compute the numerical values of $k_i$, $T$, $p_{i,\\max}$, or the full expression for $B(T)$.\n\nWe are given the following values:\n- Antigen concentration: $A = 5$ nM\n- Hill coefficient: $n = 2$\n- Old affinity: $K_d^{(\\mathrm{old})} = 10$ nM\n- New affinity: $K_d^{(\\mathrm{new})} = 1$ nM\n\nFirst, we calculate the occupancy $\\theta$ for each case.\nFor the old CAR:\n$$\n\\theta^{(\\mathrm{old})} = \\frac{A}{A + K_d^{(\\mathrm{old})}} = \\frac{5}{5 + 10} = \\frac{5}{15} = \\frac{1}{3}\n$$\nFor the new CAR:\n$$\n\\theta^{(\\mathrm{new})} = \\frac{A}{A + K_d^{(\\mathrm{new})}} = \\frac{5}{5 + 1} = \\frac{5}{6}\n$$\nNow, we can compute the ratio $R$:\n$$\nR = \\left(\\frac{\\theta^{(\\mathrm{new})}}{\\theta^{(\\mathrm{old})}}\\right)^n = \\left(\\frac{5/6}{1/3}\\right)^2 = \\left(\\frac{5}{6} \\times \\frac{3}{1}\\right)^2 = \\left(\\frac{15}{6}\\right)^2 = \\left(\\frac{5}{2}\\right)^2\n$$\n$$\nR = \\frac{25}{4} = 6.25\n$$\nThe problem requires the answer to be rounded to three significant figures. The calculated value $6.25$ is exact and already has three significant figures.", "answer": "$$\\boxed{6.25}$$", "id": "5027815"}, {"introduction": "Moving from molecular design to in-vivo population dynamics, this practice challenges you to model the engine of cytokine release syndrome (CRS). You will use a system of coupled differential equations to represent CAR-T cell expansion and the consequent production of inflammatory cytokines under an early-time approximation. Solving this system provides a foundational mathematical framework for understanding the kinetics of toxicity, illustrating how an initial cell dose can lead to an exponential surge in cytokines [@problem_id:5027597].", "problem": "A translational scientist is modeling the early kinetics of Chimeric Antigen Receptor T cells (CAR-T) after infusion to understand and manage the risk of Cytokine Release Syndrome (CRS) and immune effector Cell-Associated Neurotoxicity Syndrome (ICANS). Assume CAR-T cells expand in the host following density-dependent growth regulated by a carrying capacity, and that an inflammatory cytokine concentration is produced proportionally to the number of CAR-T cells and cleared by first-order kinetics. The foundational modeling assumptions are: density-dependent proliferation in a resource-limited environment, linear production proportional to source abundance, and first-order clearance governed by mass-action decay. Let $N(t)$ denote the CAR-T cell count and $C(t)$ denote the cytokine concentration at time $t$, with $N(0)=N_{0}>0$ and $C(0)=C_{0}\\geq 0$. The governing equations are\n$$\\frac{dN}{dt}=r\\,N\\left(1-\\frac{N}{K}\\right), \\quad \\frac{dC}{dt}=\\alpha\\,N-\\beta\\,C,$$\nwhere $r>0$ is the intrinsic CAR-T proliferation rate, $K>0$ is the effective carrying capacity, $\\alpha>0$ is the cytokine production rate per CAR-T cell, and $\\beta>0$ is the cytokine clearance rate. Under the early-time regime defined by $N(t)/K\\ll 1$, derive a closed-form analytic expression for $C(t)$ in terms of $t$, $N_{0}$, $C_{0}$, $r$, $K$, $\\alpha$, and $\\beta$ by systematically reducing the dynamics to the appropriate asymptotic form implied by the stated principles and solving the resulting initial value problem. Your final answer must be a single closed-form analytic expression for $C(t)$ and must not include any units.", "solution": "The problem statement has been rigorously validated and found to be scientifically grounded, well-posed, objective, and internally consistent. It presents a standard problem in mathematical biology and theoretical pharmacology, using established modeling principles (logistic growth, first-order kinetics) to describe the interaction between CAR-T cells and cytokines. All necessary parameters and initial conditions are provided, allowing for the derivation of a unique, meaningful solution under the specified approximation. Therefore, the problem is deemed valid and a formal solution can be constructed.\n\nThe system of ordinary differential equations governing the CAR-T cell count, $N(t)$, and the cytokine concentration, $C(t)$, is given by:\n$$\n\\frac{dN}{dt} = r\\,N\\left(1 - \\frac{N}{K}\\right)\n$$\n$$\n\\frac{dC}{dt} = \\alpha\\,N - \\beta\\,C\n$$\nThe problem requires a solution in the early-time regime, which is mathematically defined by the condition $N(t)/K \\ll 1$. This approximation simplifies the logistic growth equation for $N(t)$. The term $N/K$ becomes negligible in comparison to $1$, reducing the equation to:\n$$\n\\frac{dN}{dt} \\approx r\\,N(1 - 0) = r\\,N\n$$\nThis is the equation for exponential growth. We must solve this simplified equation for $N(t)$ subject to the initial condition $N(0) = N_0$. This is a first-order separable linear ordinary differential equation.\n$$\n\\frac{dN}{N} = r\\,dt\n$$\nIntegrating both sides from the initial state $(0, N_0)$ to a state $(t, N(t))$ yields:\n$$\n\\int_{N_0}^{N(t)} \\frac{1}{N'} dN' = \\int_{0}^{t} r\\,d\\tau\n$$\n$$\n\\ln(N(t)) - \\ln(N_0) = rt\n$$\n$$\n\\ln\\left(\\frac{N(t)}{N_0}\\right) = rt\n$$\nExponentiating both sides gives the solution for $N(t)$ in the early-time regime:\n$$\nN(t) = N_0 \\exp(rt)\n$$\nThis approximation is valid for times $t$ such that $N_0 \\exp(rt) \\ll K$.\n\nNext, we substitute this expression for $N(t)$ into the differential equation for the cytokine concentration $C(t)$:\n$$\n\\frac{dC}{dt} = \\alpha (N_0 \\exp(rt)) - \\beta\\,C\n$$\nThis can be rearranged into the standard form of a first-order linear non-homogeneous ordinary differential equation:\n$$\n\\frac{dC}{dt} + \\beta\\,C = \\alpha N_0 \\exp(rt)\n$$\nTo solve this equation, we use the method of integrating factors. The integrating factor, $\\mu(t)$, is given by:\n$$\n\\mu(t) = \\exp\\left(\\int \\beta \\, dt\\right) = \\exp(\\beta t)\n$$\nMultiplying the differential equation by $\\mu(t)$:\n$$\n\\exp(\\beta t)\\frac{dC}{dt} + \\beta \\exp(\\beta t) C = \\alpha N_0 \\exp(rt) \\exp(\\beta t)\n$$\nThe left-hand side is the derivative of the product $C(t)\\mu(t)$ by the product rule:\n$$\n\\frac{d}{dt}\\left(C(t) \\exp(\\beta t)\\right) = \\alpha N_0 \\exp((r+\\beta)t)\n$$\nWe now integrate both sides with respect to $t$:\n$$\n\\int \\frac{d}{dt}\\left(C(t) \\exp(\\beta t)\\right) dt = \\int \\alpha N_0 \\exp((r+\\beta)t) dt\n$$\n$$\nC(t) \\exp(\\beta t) = \\alpha N_0 \\int \\exp((r+\\beta)t) dt\n$$\nThe problem states that $r > 0$ and $\\beta > 0$, which implies that their sum $r+\\beta$ is strictly positive. Therefore, the integral is well-defined and non-trivial.\n$$\nC(t) \\exp(\\beta t) = \\alpha N_0 \\left(\\frac{1}{r+\\beta}\\right) \\exp((r+\\beta)t) + C_{\\text{int}}\n$$\nwhere $C_{\\text{int}}$ is the constant of integration. To find the general solution for $C(t)$, we divide by the integrating factor $\\exp(\\beta t)$:\n$$\nC(t) = \\frac{\\alpha N_0}{r+\\beta} \\frac{\\exp((r+\\beta)t)}{\\exp(\\beta t)} + C_{\\text{int}} \\exp(-\\beta t)\n$$\n$$\nC(t) = \\frac{\\alpha N_0}{r+\\beta} \\exp(rt) + C_{\\text{int}} \\exp(-\\beta t)\n$$\nTo determine the constant $C_{\\text{int}}$, we apply the initial condition $C(0) = C_0$:\n$$\nC(0) = C_0 = \\frac{\\alpha N_0}{r+\\beta} \\exp(r \\cdot 0) + C_{\\text{int}} \\exp(-\\beta \\cdot 0)\n$$\n$$\nC_0 = \\frac{\\alpha N_0}{r+\\beta} (1) + C_{\\text{int}} (1)\n$$\nSolving for $C_{\\text{int}}$ yields:\n$$\nC_{\\text{int}} = C_0 - \\frac{\\alpha N_0}{r+\\beta}\n$$\nFinally, substituting this expression for $C_{\\text{int}}$ back into the general solution for $C(t)$ gives the closed-form analytic expression for the cytokine concentration in the early-time regime:\n$$\nC(t) = \\frac{\\alpha N_0}{r+\\beta} \\exp(rt) + \\left(C_0 - \\frac{\\alpha N_0}{r+\\beta}\\right) \\exp(-\\beta t)\n$$\nThis expression captures the dynamics of cytokine concentration as a superposition of two processes: an exponential increase driven by the proliferation of CAR-T cells (proportional to $\\exp(rt)$) and an exponential decay of the initial cytokine concentration adjusted by the CAR-T contribution (proportional to $\\exp(-\\beta t)$).", "answer": "$$\n\\boxed{\\frac{\\alpha N_{0}}{r+\\beta} \\exp(rt) + \\left(C_{0} - \\frac{\\alpha N_{0}}{r+\\beta}\\right) \\exp(-\\beta t)}\n$$", "id": "5027597"}, {"introduction": "This final practice brings our modeling concepts to the clinical bedside, where timely decisions are critical for patient safety. You will apply a statistical decision model that integrates multiple circulating biomarkers—each with its own predictive weight—to calculate a real-time risk score for severe CRS. This exercise demonstrates how complex, dynamic biological processes can be distilled into an actionable algorithm, bridging the gap between patient data and evidence-based therapeutic intervention [@problem_id:5027695].", "problem": "A patient with diffuse large B-cell lymphoma has received Chimeric Antigen Receptor T-cell (CAR-T) therapy. Within $48$ hours of infusion, the team monitors for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity, using circulating biomarkers Interleukin-6 (IL-6), C-reactive protein (CRP), and ferritin, which are known correlates of systemic inflammation. Assume the following well-established bases: (i) for a biomarker $b$ measured relative to a reference median $b_{0}$, a doubling of $b/b_{0}$ increases $\\log_{2}(b/b_{0})$ by $1$; (ii) in a short observation window with rare events, odds ratios approximate hazard ratios; (iii) under a proportional hazards framework, a reported hazard ratio per doubling, $\\mathrm{HR}$, corresponds to an additive increment of $\\ln(\\mathrm{HR})$ in the log-odds for each unit increase of $\\log_{2}(b/b_{0})$; and (iv) a decision index $D$ on $[0,1]$ can be obtained by mapping a linear predictor to a probability using the standard logistic link. The intercept is chosen to satisfy $D=\\tfrac{1}{2}$ when each biomarker equals its reference median.\n\nYou are given the patient’s laboratory values obtained at $t=24$ hours post-infusion: IL-6 $=420\\ \\mathrm{pg/mL}$, CRP $=200\\ \\mathrm{mg/L}$, ferritin $=2500\\ \\mathrm{ng/mL}$. Use the following reference medians for non-CRS baseline: IL-6 $=10\\ \\mathrm{pg/mL}$, CRP $=5\\ \\mathrm{mg/L}$, ferritin $=300\\ \\mathrm{ng/mL}$. Published hazard ratios per doubling for progression to grade $\\geq 2$ CRS in this time window are: IL-6 $\\mathrm{HR}=2.7$, CRP $\\mathrm{HR}=1.8$, ferritin $\\mathrm{HR}=1.5$. The clinical protocol initiates anti-IL-6 therapy when the decision index satisfies $D \\geq \\theta$, with $\\theta=0.65$.\n\nStarting only from the bases above, derive the decision index from first principles and compute its value for this patient. Express the decision index $D$ as a dimensionless decimal rounded to four significant figures. Do not include any unit in your final numeric answer.", "solution": "The objective is to derive the decision index $D$ from the provided principles and compute its value for the patient. The decision index is a score between $0$ and $1$ that quantifies the risk of progressing to grade $\\geq 2$ Cytokine Release Syndrome (CRS).\n\nFirst, as per basis (iv), the decision index $D$ is related to a linear predictor, $\\eta$, through the standard logistic link function:\n$$D = \\frac{1}{1 + \\exp(-\\eta)}$$\nThe linear predictor $\\eta$ is a composite score calculated from the patient's biomarker levels. It is a linear combination of predictor variables, one for each biomarker:\n$$\\eta = \\beta_0 + \\beta_{IL-6} X_{IL-6} + \\beta_{CRP} X_{CRP} + \\beta_{Frt} X_{Frt}$$\nHere, $\\beta_0$ is the intercept, the $\\beta_i$ are the coefficients for each biomarker, and the $X_i$ are the corresponding predictor variables.\n\nBasis (i) defines the predictor variable for a biomarker $b$ with a reference median $b_0$ as $X = \\log_2(b/b_0)$. This logarithmic transformation ensures that a doubling of the biomarker-to-reference ratio results in a unit increase in $X$. For the three specified biomarkers, the predictor variables are:\n$$X_{IL-6} = \\log_2\\left(\\frac{b_{IL-6}}{b_{0, IL-6}}\\right)$$\n$$X_{CRP} = \\log_2\\left(\\frac{b_{CRP}}{b_{0, CRP}}\\right)$$\n$$X_{Frt} = \\log_2\\left(\\frac{b_{Frt}}{b_{0, Frt}}\\right)$$\n\nBasis (iii) establishes the relationship between the hazard ratio ($\\mathrm{HR}$) per doubling and the coefficients $\\beta_i$ in the linear predictor. The coefficient for each predictor variable is the natural logarithm of its corresponding hazard ratio:\n$$\\beta_{IL-6} = \\ln(\\mathrm{HR}_{IL-6})$$\n$$\\beta_{CRP} = \\ln(\\mathrm{HR}_{CRP})$$\n$$\\beta_{Frt} = \\ln(\\mathrm{HR}_{Frt})$$\n\nThe intercept $\\beta_0$ is determined using the condition provided in basis (iv): $D = \\frac{1}{2}$ when each biomarker is equal to its reference median ($b_i = b_{0,i}$). At this baseline state, the ratio $b_i/b_{0,i} = 1$, and thus each predictor variable $X_i = \\log_2(1) = 0$. The linear predictor simplifies to $\\eta_{baseline} = \\beta_0 + 0 + 0 + 0 = \\beta_0$.\nSetting $D=\\frac{1}{2}$ for $\\eta = \\beta_0$:\n$$\\frac{1}{2} = \\frac{1}{1 + \\exp(-\\beta_0)}$$\n$$2 = 1 + \\exp(-\\beta_0)$$\n$$\\exp(-\\beta_0) = 1$$\nTaking the natural logarithm of both sides gives $-\\beta_0 = \\ln(1) = 0$, which implies that the intercept $\\beta_0 = 0$.\n\nCombining these principles, the full expression for the linear predictor is:\n$$\\eta = \\ln(\\mathrm{HR}_{IL-6}) \\log_2\\left(\\frac{b_{IL-6}}{b_{0, IL-6}}\\right) + \\ln(\\mathrm{HR}_{CRP}) \\log_2\\left(\\frac{b_{CRP}}{b_{0, CRP}}\\right) + \\ln(\\mathrm{HR}_{Frt}) \\log_2\\left(\\frac{b_{Frt}}{b_{0, Frt}}\\right)$$\nUsing the change of base formula for logarithms, $\\log_2(x) = \\frac{\\ln(x)}{\\ln(2)}$, we can write $\\eta$ in terms of natural logarithms for easier computation:\n$$\\eta = \\frac{1}{\\ln(2)} \\left[ \\ln(\\mathrm{HR}_{IL-6}) \\ln\\left(\\frac{b_{IL-6}}{b_{0, IL-6}}\\right) + \\ln(\\mathrm{HR}_{CRP}) \\ln\\left(\\frac{b_{CRP}}{b_{0, CRP}}\\right) + \\ln(\\mathrm{HR}_{Frt}) \\ln\\left(\\frac{b_{Frt}}{b_{0, Frt}}\\right) \\right]$$\n\nNow, we substitute the patient's data and the given parameters:\nPatient's values: $b_{IL-6} = 420$, $b_{CRP} = 200$, $b_{Frt} = 2500$.\nReference medians: $b_{0, IL-6} = 10$, $b_{0, CRP} = 5$, $b_{0, Frt} = 300$.\nHazard Ratios: $\\mathrm{HR}_{IL-6} = 2.7$, $\\mathrm{HR}_{CRP} = 1.8$, $\\mathrm{HR}_{Frt} = 1.5$.\n\nFirst, compute the biomarker ratios:\n$$\\frac{b_{IL-6}}{b_{0, IL-6}} = \\frac{420}{10} = 42$$\n$$\\frac{b_{CRP}}{b_{0, CRP}} = \\frac{200}{5} = 40$$\n$$\\frac{b_{Frt}}{b_{0, Frt}} = \\frac{2500}{300} = \\frac{25}{3}$$\n\nNext, we calculate the components of $\\eta$:\n$$\\eta = \\frac{1}{\\ln(2)} \\left[ \\ln(2.7)\\ln(42) + \\ln(1.8)\\ln(40) + \\ln(1.5)\\ln\\left(\\frac{25}{3}\\right) \\right]$$\nNumerically evaluating the terms:\n$\\ln(2) \\approx 0.693147$\n$\\ln(2.7) \\approx 0.993252$\n$\\ln(1.8) \\approx 0.587787$\n$\\ln(1.5) \\approx 0.405465$\n$\\ln(42) \\approx 3.737670$\n$\\ln(40) \\approx 3.688879$\n$\\ln(25/3) \\approx 2.120264$\n\nThe individual products in the expression for $\\eta$ are:\n- IL-6 term: $\\ln(2.7)\\ln(42) \\approx (0.993252)(3.737670) \\approx 3.71263$\n- CRP term: $\\ln(1.8)\\ln(40) \\approx (0.587787)(3.688879) \\approx 2.16843$\n- Ferritin term: $\\ln(1.5)\\ln(25/3) \\approx (0.405465)(2.120264) \\approx 0.85966$\n\nThe sum of these products is: $3.71263 + 2.16843 + 0.85966 \\approx 6.74072$.\nThe linear predictor is:\n$$\\eta = \\frac{6.74072}{0.693147} \\approx 9.72480$$\nFinally, we compute the decision index $D$:\n$$D = \\frac{1}{1 + \\exp(-\\eta)} = \\frac{1}{1 + \\exp(-9.72480)}$$\nThe exponential term has a value of $\\exp(-9.72480) \\approx 5.979 \\times 10^{-5}$.\n$$D = \\frac{1}{1 + 0.00005979} = \\frac{1}{1.00005979} \\approx 0.99994021$$\nRounding the result to four significant figures as required gives:\n$$D \\approx 0.9999$$\nThis value is well above the treatment threshold of $\\theta = 0.65$.", "answer": "$$\\boxed{0.9999}$$", "id": "5027695"}]}